This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will DuPont de Nemours (DD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
DuPont de Nemours (DD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Market Edge Highlights: DuPont, Nutrien, Transcat, Heritage Crystal Clean and Boot Barn
by Zacks Equity Research
Zacks Market Edge Highlights: DuPont, Nutrien, Transcat, Heritage Crystal Clean and Boot Barn
How to Use the Zacks Rank to Find Hidden Gem Stocks
by Tracey Ryniec
Look beyond FAANG to find unknown companies with the possibility of tremendous growth and value.
DuPont (DD) Wraps Up Laird Performance Materials Buyout
by Zacks Equity Research
DuPont (DD) along with Laird Performance Materials is expected to leverage its extensive customer base and global scale to accelerate speed to market.
Top Ranked Income Stocks to Buy for June 30th
by Zacks Equity Research
IPG, NEXA, FBIZ, and DD made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 30, 2021
U.S. Chemical Volumes Set for An Upswing in 2021: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for an upturn this year on strength across major end-markets, higher industrial activities and a recovery in chemical exports. UNVR, CBT, DD, OLN and DOW are worth a wager right now.
After Plunging 8.8% in 4 Weeks, Here's Why the Trend Might Reverse for DuPont de Nemours (DD)
by Zacks Equity Research
The heavy selling pressure might have exhausted for DuPont de Nemours (DD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
4 Stocks to Watch in the Growing Nanotechnology Market
by Kaustav Ghosh
Watch out for names like Onto Innovation (ONTO), DuPont de Nemours (DD), Thermo Fisher Scientific (TMO) and International Business Machines (IBM) as the nanotechnology market continues to grow.
Why Is DuPont de Nemours (DD) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
DuPont de Nemours (DD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Estimates Rising for DuPont de Nemours (DD): Will It Gain?
by Zacks Equity Research
DuPont de Nemours (DD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why You Should Add DuPont (DD) to Your Portfolio
by Zacks Equity Research
DuPont (DD) gains from strong demand, cost actions and innovation-driven investment.
DuPont (DD) Invests $5M in European Production Resources
by Zacks Equity Research
DuPont (DD) invests $5 million toward R&D and procurement of new equipment for its German and Swedish facilities, to accelerate growth in hybrid and electric vehicles.
DuPont de Nemours (DD) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does DuPont de Nemours (DD) have what it takes to be a top stock pick for momentum investors? Let's find out.
DuPont de Nemours (DD) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
DuPont (DD) Up 23% in 3 Months: What's Driving the Stock?
by Zacks Equity Research
Solid first-quarter results and upbeat outlook have contributed to the run-up in DuPont's (DD) shares.
International Flavors (IFF) Q1 Earnings & Sales Top Estimates
by Zacks Equity Research
International Flavors' (IFF) Q1 top-line results gain from incremental sales related to the merger deal as well as strong performances in Scent & Pharma Solutions.
DuPont de Nemours (DD) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
DuPont's (DD) Earnings and Revenues Trounce Estimates in Q1
by Zacks Equity Research
DuPont (DD) benefits from strength in semiconductors and smartphone technologies, continued recovery in automotive and industrial markets and strong demand for water filtration technologies in Q1.
DuPont de Nemours (DD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DuPont de Nemours (DD) delivered earnings and revenue surprises of 18.18% and 4.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Diversified Chemical Stocks Set to Ride the Industry's Upswing
by Anindya Barman
An upturn in demand in major end-markets from the pandemic-induced slump should enable the Zacks Chemicals Diversified industry to thrive. DOW, PPG, OLN and CBT are set to gain from the improving industry fundamentals and strategic actions.
Should You Buy DuPont (DD) Ahead of Earnings?
by Zacks Equity Research
DuPont (DD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
by Anindya Barman
An uptick in end-market demand and benefits of self-help actions are likely to reflect on the performance of DuPont (DD), Westlake (WLK), Koppers (KOP) and Trinseo (TSE) in Q1.
DuPont (DD) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from its cost and productivity actions in Q1. However, weaker nylon prices may have affected its performance.
Materials Sector to Rejoice in Q1 Earnings: ETFs to Play
by Sweta Killa
The solid trend for materials ETFs is likely to continue as Q1 earnings unfold.
Why DuPont de Nemours (DD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
DuPont de Nemours (DD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.